Decreased Muscle Mass Linked with Higher Toxicity, Poorer Prognosis Risk in Colon Cancer
the Cancer Therapy Advisor take:
Decreased muscle mass is associated with an increased risk of grade 3/4 toxicity and poorer prognosis in patients with stage 3 colon cancer, according to a recent study published in Supportive Care in Cancer.
Korean researchers led by Hee-Won Jung, MD, at the Seoul National University College of Medicine examined data on 229 patients with stage 3 colon cancer who received adjuvant oxaliplatin, 5-fluorouracil, and leucovorin chemotherapy from 2003 to 2010, measuring for effects of muscle mass on toxicity and survival. Median age was 61 years and 134 patients were male.
The researchers found that decrease in muscle mass was associated with increased toxicity in all grade 3/4 cancers in univariate and multivariate analyses.
In multivariate analysis alone, they found that an incremental decrease in muscle mass index increased the hazard of overall mortality.
The effect was further confirmed in subgroup analyses and it was further pronounced in patients who were older and obese.
Decreased muscle mass is associated with an increased risk of grade 3/4 toxicity and poorer prognosis in stage 3 colon cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Bowel Preparation for Colorectal Cancer Screening: Improving Outcomes
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia
- BTK Inhibitor Zanubrutinib Appears Promising in Waldenström Macroglobulinemia
- Carfilzomib Regimens Offer a Neuropathy-Sparing Approach in Multiple Myeloma, WM
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer